Mod GRF 1-29 vs CJC-1295 DAC: What's the Real Difference?

Mod GRF 1-29 and CJC-1295 DAC are both growth hormone-releasing hormone (GHRH) analogs, but they differ in one decisive way: half-life. CJC-1295 with DAC carries a drug affinity complex that binds to albumin and keeps it active for roughly 6 to 8 days, while Mod GRF 1-29 — often sold as CJC-1295 without DAC — clears from the bloodstream in about 30 minutes. That single structural change drives every other difference between them, from GH pulse shape to how often each is injected in research settings.

What Mod GRF 1-29 Actually Is

Mod GRF 1-29 is a stabilized version of the first 29 amino acids of natural human GHRH. Four amino acid substitutions make it resistant to rapid enzymatic breakdown, but it remains a short-acting peptide.

Because it clears quickly, Mod GRF 1-29 produces a brief, sharp rise in growth hormone that closely mimics the body's natural pulsatile release. Researchers frequently pair it with a ghrelin-receptor agonist such as ipamorelin to amplify that pulse.

The naming is the source of most online confusion. The label "cjc-1295 mod grf 1-29 without dac" appears constantly in supplier listings and forum threads, yet plain CJC-1295 in the scientific literature refers to the long-acting DAC version. When a product says "no DAC," it means this short-acting peptide.

What CJC-1295 With DAC Actually Is

CJC-1295 with DAC uses the same 29-amino-acid GHRH backbone, but it adds a maleimidopropionic acid linker that binds covalently to serum albumin. Albumin acts as a carrier protein and shields the peptide from the enzymes that would otherwise destroy it.

Published research in healthy adult volunteers found that a single dose raised growth hormone and IGF-1 levels for up to about six days afterward. That extended window is why CJC-1295 DAC is described as a long-acting GHRH analog.

CJC-1295 with DAC is not a different hormone from Mod GRF 1-29 — it is the same core peptide with a delivery-enhancing tail attached.

Mod GRF 1-29 vs CJC-1295 DAC: Side-by-Side Comparison

Feature	Mod GRF 1-29 (CJC-1295 No DAC)	CJC-1295 With DAC
Half-life	About 30 minutes	About 6 to 8 days
Albumin binding	None	Yes, via the DAC linker
GH release pattern	Short, pulse-like	Prolonged and sustained
Typical research dose	Roughly 100 mcg per administration	Roughly 1 to 2 mg per week
Injection frequency in studies	2 to 3 times daily	Once weekly
Common label names	Mod GRF 1-29, CJC-1295 no DAC	CJC-1295 DAC, CJC-1295
FDA-approved for human use	No	No

Dosing and Frequency in Research Settings

The two peptides are studied on very different schedules because their clearance rates are so far apart.

• Mod GRF 1-29: typically around 100 mcg per administration, often two or three times daily, timed near natural GH pulses such as before sleep or after training.
• CJC-1295 DAC: typically around 1 to 2 mg per week as a single injection, because one dose stays active for days.

These figures come from published research protocols, not from FDA-approved prescribing information. Anyone comparing mod grf 1 29 vs cjc 1295 dac for personal use should treat dosing tables on vendor sites as marketing rather than clinical guidance.

Which One Do Researchers Choose?

The question "cjc-1295 dac vs no dac which is better" does not have one universal answer. It depends entirely on what a study is trying to model.

Investigators who want to replicate the body's natural pulsatile GH rhythm tend to favor the short-acting peptide. Those studying sustained IGF-1 elevation or long-window exposure tend to choose the DAC version.

Convenience plays a role too. A weekly injection is far easier to manage than multiple daily injections, which is a large part of why this comparison keeps resurfacing in fitness and longevity communities.

Related GHRH Options Worth Comparing

Mod GRF 1-29 is not the only short-acting GHRH analog in circulation. Anyone weighing cjc 1295 no dac vs sermorelin is comparing two short-acting peptides, since sermorelin is essentially GHRH(1-29) without Mod GRF's four stabilizing substitutions.

Tesamorelin is another GHRH analog, and unlike the rest it holds an FDA-approved indication for HIV-associated lipodystrophy. Searches for tesamorelin vs cjc-1295 no dac usually come down to that regulatory gap as much as to pharmacology.

Stacking is a common research theme as well. The comparison sermorelin vs cjc-1295 no dac ipamorelin reflects study designs that combine a GHRH analog with a ghrelin-receptor agonist to test whether GH release is additive.

Even the phrase cjc-1295 vs cjc-1295 dac is mostly a naming problem: both labels describe the same GHRH backbone, separated only by the DAC linker.

Safety, Sourcing, and Legal Status

Neither Mod GRF 1-29 nor CJC-1295 DAC is FDA-approved for human use in the United States. Both are sold as research chemicals, which means purity, dosing accuracy, and sterility are not guaranteed by any regulator.

Reported effects in published studies include injection-site irritation, flushing, and temporary fluid retention. Long-term safety data in healthy people remain limited, and deliberately altering growth hormone and IGF-1 levels is not a trivial intervention.

Anyone considering these peptides for personal use should discuss it with a healthcare professional rather than relying on vendor claims or forum anecdotes. IGF-1 elevation in particular warrants medical oversight.

COMMON QUESTIONS

Frequently Asked Questions

Is Mod GRF 1-29 the same as CJC-1295 without DAC?

Yes. Mod GRF 1-29 and CJC-1295 without DAC are two names for the same short-acting GHRH analog, and both refer to the peptide without the albumin-binding DAC linker. Vendors often list it as "CJC-1295 no DAC" or "Mod GRF 1-29," which creates confusion with the long-acting CJC-1295 DAC product.

Which lasts longer, Mod GRF 1-29 or CJC-1295 DAC?

CJC-1295 with DAC lasts far longer. Its half-life is roughly 6 to 8 days because the DAC linker binds it to serum albumin, while Mod GRF 1-29 has a half-life of about 30 minutes. That gap is why CJC-1295 DAC is studied as a weekly injection and Mod GRF 1-29 as a multiple-daily one.

Is CJC-1295 DAC FDA-approved?

No. CJC-1295 with DAC is not FDA-approved for any human use in the United States and is sold only as a research chemical. Tesamorelin is the GHRH analog that holds an FDA-approved indication, and it is approved specifically for HIV-associated lipodystrophy rather than for general wellness or performance use.